Alto Neuroscience ANRO Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's cash & equivalents?
- Alto Neuroscience (ANRO) reported cash & equivalents of $264.26M in Q1 2026.
- How has Alto Neuroscience's cash & equivalents changed year-over-year?
- Alto Neuroscience's cash & equivalents increased by 63.9% year-over-year, from $161.25M to $264.26M.
- What is the long-term trend for Alto Neuroscience's cash & equivalents?
- Over 3 years (2022 to 2025), Alto Neuroscience's cash & equivalents has grown at a 54.1% compound annual growth rate (CAGR), from $48.34M to $176.98M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.